RESUMO
Schizophrenia is one of the most debilitating disorders with devastating effects on its victims and their families. Atypical antipsychotics (AAPs) because of their superior efficacy, reduced side effects, & better compliance, have rapidly become the mainstay of treatment. But, because of paucity of research & literature on the long-term metabolic side effect profile of these AAPs in Indian setup, this prospective study has been carried out to compare the effects of olanzapine & risperidone on body weight, body mass index, & blood sugar level in schizophrenic patients. Among 60 newly diagnosed DSM-IV patients of schizophrenia enrolled, it was observed that mean body weight & BMI were significantly increased from baseline to 6 & 12 weeks in both olanzapine (n=30) & risperidone groups (n=30) (P<0.001). Also, mean blood sugar was found to be significantly elevated after 6 & 12 weeks of treatment with olanzapine (P<0.001) but not in risperidone group. Thus, the present study underscores the need for baseline and six weekly monitoring of body weight and blood glucose in routine clinical practice with AAPs.
RESUMO
Effect of pretreatment of intraperitoneally administered Ca-channel blockers Nifedipine (5, 10, 20 mg/kg). Verapamil (5, 10, 20 mg/kg) and Diltiazem (5, 10, 20 mg/kg) was studied on Haloperidol-induced catalepsy and Methamphetamine-induced stereotypy in albino rats. All these drugs reduced the onset of catalepsy, significantly increased the cataleptic score and delayed the onset and inhibited the Methamphetamine-induced stereotypy. The possible involvement of dopaminergic and adrenergic mechanisms and modification by Ca-channel blockers are discussed.